Intranasal ELI 200 Human Abuse Liability (HAL) trial: A double-blind, randomised 5-way crossover study

Trial Profile

Intranasal ELI 200 Human Abuse Liability (HAL) trial: A double-blind, randomised 5-way crossover study

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs ELI 200 (Primary) ; ELI 200 (Primary) ; Oxycodone
  • Indications Opioid abuse
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Elite Pharmaceuticals
  • Most Recent Events

    • 09 May 2016 Pharmacodynamic data assessing the abuse potential will be presented at the American Pain Society 35th Annual Scientific Meeting 2016, according to an Elite Pharmaceuticals media release.
    • 17 Sep 2014 New trial record
    • 09 Sep 2014 Primary endpoint has been met. (the peak effect (E max ) for Drug Liking).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top